Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Transplantation of olfactory ensheathing cells, the glia of the primary olfactory nervous system, has been trialed for spinal cord injury repair with promising but variable outcomes in animals and humans. Olfactory ensheathing cells can be harvested either from the lamina propria beneath the neuroepithelium in the nasal cavity, or from the olfactory bulb in the brain. As these areas contain several other cell types, isolating and purifying olfactory ensheathing cells is a critical part of the process. It is largely unknown how contaminating cells such as fibroblasts, other glial cell types and supporting cells affect olfactory ensheathing cell function post-transplantation; these cells may also cause unwanted side-effects. It is also, however, possible that the presence of some of the contaminant cells can improve outcomes. Here, we reviewed the last decade of olfactory ensheathing cell transplantation studies in rodents, with a focus on olfactory ensheathing cell purity. We analyzed how purification methods and resultant cell purity differed between olfactory mucosa- and olfactory bulb-derived cell preparations. We analyzed how the studies reported on olfactory ensheathing cell purity and which criteria were used to define cells as olfactory ensheathing cells. Finally, we analyzed the correlation between cell purity and transplantation outcomes. We found that olfactory bulb-derived olfactory ensheathing cell preparations are typically purer than mucosa-derived preparations. We concluded that there is an association between high olfactory ensheathing cell purity and favourable outcomes, but the lack of olfactory ensheathing cell-specific markers severely hampers the field.

Free full text 


Logo of nrrHomeCurrent issueInstructionsSubmit article
Neural Regen Res. 2020 Nov; 15(11): 2016–2026.
Published online 2020 May 11. https://doi.org/10.4103/1673-5374.282218
PMCID: PMC7716040
PMID: 32394949

Reliable cell purification and determination of cell purity: crucial aspects of olfactory ensheathing cell transplantation for spinal cord repair

Ronak Reshamwala,1,2,3 Megha Shah,2,3 Lucy Belt,2,3 Jenny A. K. Ekberg, PhD,1,2,3,* and James A. St John, PhD1,2,3,*

Associated Data

Supplementary Materials

Abstract

Transplantation of olfactory ensheathing cells, the glia of the primary olfactory nervous system, has been trialed for spinal cord injury repair with promising but variable outcomes in animals and humans. Olfactory ensheathing cells can be harvested either from the lamina propria beneath the neuroepithelium in the nasal cavity, or from the olfactory bulb in the brain. As these areas contain several other cell types, isolating and purifying olfactory ensheathing cells is a critical part of the process. It is largely unknown how contaminating cells such as fibroblasts, other glial cell types and supporting cells affect olfactory ensheathing cell function post-transplantation; these cells may also cause unwanted side-effects. It is also, however, possible that the presence of some of the contaminant cells can improve outcomes. Here, we reviewed the last decade of olfactory ensheathing cell transplantation studies in rodents, with a focus on olfactory ensheathing cell purity. We analyzed how purification methods and resultant cell purity differed between olfactory mucosa- and olfactory bulb-derived cell preparations. We analyzed how the studies reported on olfactory ensheathing cell purity and which criteria were used to define cells as olfactory ensheathing cells. Finally, we analyzed the correlation between cell purity and transplantation outcomes. We found that olfactory bulb-derived olfactory ensheathing cell preparations are typically purer than mucosa-derived preparations. We concluded that there is an association between high olfactory ensheathing cell purity and favourable outcomes, but the lack of olfactory ensheathing cell-specific markers severely hampers the field.

Keywords: antibody, astrocyte, fibroblast, glia, glial cell, injury, nerve, neuron trauma, surgery

Introduction

Olfactory ensheathing cells (OECs) are considered crucial for the constant regeneration of the primary olfactory nervous system that occurs throughout life (Graziadei and Graziadei, 1979; Graziadei and Monti Graziadei, 1980, 1985). For this reason, transplantation of OECs to repair the injured nervous system, in particular the spinal cord, has been the focus of research efforts over the last two decades (Munoz-Quiles et al., 2009; Granger et al., 2012; Tabakow et al., 2013, 2014). In their natural environment, OECs support and guide olfactory axons as they continuously extend from the olfactory mucosa (OM) to their target synaptic regions in the olfactory bulb (OB). The concept of OEC transplantation is to replicate the same process in the injured spinal cord, resulting in axonal regeneration through the injury site and re-establishment of conductive pathways. The mechanisms by which OECs promote neural regeneration, both in their natural location and after transplantation, include direct interaction with axons and structural support (Doucette, 1989, 1990), secretion of neurotrophic and guidance factors (Barnett and Riddell, 2004; Barton et al., 2017), phagocytosis of axonal debris as well as effective migration and integration with other cell types such as astrocytes and microglia (Lakatos et al., 2000, 2003; Vincent et al., 2007; Leung et al., 2008; Panni et al., 2013).

Conceptually, the use of OEC transplantation to repair damaged axons following a spinal cord injury is quite simple and robust; OECs are harvested from the olfactory nerve, expanded in vitro for several weeks, and then transplanted (usually autologously in humans) into the injured spinal cord. The method is, however, complicated by a great variability in anatomical cell source, purification methods, and inconsistencies in reporting on issues such as OEC purity. Purification here implies the process to increase the proportion of OECs present in the total cell population, with purity referring to the proportion of OECs present in a transplantation cell population.

Several studies have shown that OECs can restore lost function and structure of an injured spinal cord (Deumens et al., 2006; Toft et al., 2007) but outcomes are variable. One potential reason for this variability is that the purity of OEC transplants is highly variable between studies. Furthermore, OECs can be harvested from either the OM or the OB, where different cell populations are present (Yao et al., 2018). Thus, the anatomical source from which the OECs are harvested and the resultant cell purity are likely to have significant impacts on outcomes after transplantation into the injured spinal cord. While it is often suggested that poorly purified OEC transplants are associated with poor outcomes and side-effects, several studies have found that the presence of fibroblasts in the OEC transplants can be beneficial (Li et al., 1997; Raisman and Li, 2007). One possible reason for this may be that fibroblasts together with OECs maintain channel-like structures through which regenerating axons can extend, which happens in the natural environment of the olfactory nerve (Li et al., 2005).

We have conducted a review of the recent literature to identify and evaluate different factors affecting the purity of the transplanted OECs, discuss the different established ways to identify and quantify the OECs and highlight the impact of the purity on the transplantation outcomes to help guide the future works into the OEC mediated SCI repair.

In this review, covering the last decade of OEC transplantation studies in rodent models of spinal cord injury, we assessed how the anatomical site of isolation (OM versus OB) affected OEC purification methods and resultant cell purity. We analyzed how many studies reported on OEC purity, and which criteria (markers) were used to define cells as OECs. Finally, we attempted to correlate transplantation outcomes with OEC purity and anatomical source. We found that high OEC purity appears associated with better outcomes, but also that purifying OECs and reporting on cell purity is very difficult due to the lack of cell-specific markers. We found that a panel of markers, along with the identification of novel markers, is crucial for improving the therapeutic potential of OEC transplantation for neural repair. The findings are summarized in Figure 1.

An external file that holds a picture, illustration, etc.
Object name is NRR-15-2016-g001.jpg

Overview of OEC collection, characteristics and purification.

OECs can be obtained from biopsies taken either from olfactory mucosa or olfactory bulb. The figure shows all the different cell types that can be found in each type of biopsy and various markers reported to be expressed by each cell type. The figure also summarizes different methods of purification depending on the source of cells and reported proportions of OECs acquired as a result of purification. AC: Astrocytes; FB: fibroblasts; FBm: meningeal fibroblast; GFAP: glial fibrillary acid protein; HNK1: human natural killer antigen-1; IBA1: ionised calcium binding adapter molecule 1; MG: microglia; MSC: mesenchymal stem cell; NB: neuronal cell bodies; NT-3: neurotrophin-3; OB: olfactory bulb; ODC: oligodendrocytes; OEC: olfactory ensheathing cells; OM: olfactory mucosa; RE: respiratory epithelium; SC: Schwann cells; O4: oligodendrocyte marker 4; p75NTR: p75 neurotrophin receptor; SOX10: Sry-related HMG-Box gene 10; Thy1: thymus cell antigen 1; TUJ1: neuron-specific class III β-tubulin.

Since surface markers are key to determining purity, this review was limited to studies that used rodents as the source of OECs. As most pre-clinical studies to date have been conducted in rodents, and because the expression of many markers varies between rodents and humans, this review was limited to rodent studies. We do, however, comment on the applicability of using certain markers for transplantation of human OECs. A literature search was conducted using the search terms “spinal cord injury”, “olfactory ensheathing cells”, “OECs”, “olfactory ensheathing glia”, “OEGs” and “olfactory glia”. The search was restricted to the studies published since 2008. Only studies using primary OECs for transplantation were included and review articles were excluded. Studies limited to in vitro experiments, peripheral or cranial nerve repair or focusing on brain injury were also excluded, as this review focuses on the OEC purification and quantification methods employed for spinal cord injury repair only. A total of 67 studies that met the inclusion criteria were included. For each study, details regarding anatomical sources of cells, methods of purification (including method of harvesting cells and enrichments/supplements used), reported purity, method to determine purity, presence of other cell types and structural/functional outcomes of each study are outlined in Additional Table 1.

Anatomical Source of Cells Affects Purity

The primary olfactory nervous system is comprised of the olfactory neuroepithelium, olfactory nerve and outer layer of the OB, known as nerve fibre layer (NFL). The olfactory nerve consists of numerous fascicles which extend from the lamina propria beneath the neuroepithelium to the NFL. Within this system, OECs are found in the olfactory nerve and the NFL of the OB In the olfactory nerve, OECs ensheathe axon fascicles, and in the NFL, they contribute to the complex sorting and organization of axons to their correct glomeruli (synapse regions) in the OB (Doucette, 1984, 1989, 1990). For transplantation purposes, OECs can therefore be harvested either from the OM (which contains lamina propria-derived OECs) or from the OB (which contains NFL-derived OECs). OECs harvested from the OM are typically termed OM-OECs, and OB-derived OECs are termed OB-OECs (Mayeur et al., 2013; Yao et al., 2018); these terms will be used throughout this article.

In humans, harvesting OB-OECs from live patients requires invasive brain surgery (Tabakow et al., 2014), and, as the OB is part of the central nervous system, this invasive approach results in permanent neurological injury. Therefore, the OM is the more preferable source of OECs from a clinically viable point-of-view (Bianco et al., 2004; Lima et al., 2006; Gorrie et al., 2010; Ekberg and St John, 2015).

It is, however, important to note that OECs are not a homologous cell population; sub-populations with distinct anatomical location and behaviors exist (Ekberg and St John, 2015). For example, OM-OECs primarily adhere to each other, resulting in contact-mediated migration, and they mediate axon fasciculation. In contrast, OB-OECs display a mixed behaviour of interaction and repulsion, and axons cultured with OB-OECs display a disorganized extension pattern (Windus et al., 2007, 2010, 2011). Another important difference between the OM and OB is the other cell types that are present with OECs in the two areas. In the OB, astrocytes, oligodendrocytes, microglia, neuronal cell bodies and meningeal fibroblasts along with endothelial cells are the most common cells. Most of these cells can be avoided if only the NFL is harvested to obtain OECs (Doucette, 1984). Even then, however, astrocytes are still present along with occasional neuronal bodies. Conversely, in the mucosal biopsies, mesenchymal stem cells, fibroblasts, Schwann cells from the trigeminal nerve and olfactory or respiratory epithelium may be found with OECs (Ekberg and St John, 2014; Yao et al., 2018). Whilst other cell contaminating cells can be found in glial cultures, neurons typically do not survive and are not present in the cultures (Windus et al., 2007, 2010); olfactory neurons typically require a monolayer of glia/specific glia-conditioned medium and stringent culture conditions to survive (Ekberg et al., 2011; Gong, 2012).

Instances have been recorded where patients have suffered serious adverse effects of receiving OEC transplants without proper purification (Yao et al., 2018). In recent years, case reports have discussed particularly alarming cases with patients who developed intramedullary masses in the cervical spine many years following transplantation of autografts from mucosal biopsies. These cysts have been found to contain respiratory epithelium and submucosal glands with goblet cells; thus, it appears that the transplants have mistakenly contained respiratory epithelial mucosa (Dlouhy et al., 2014; Woodworth et al., 2019). The first recorded incidence was in a young female who developed the mass 8 years after the transplantation (Dlouhy et al., 2014), and the most recent published case report described a 38-year-old male who presented with the mass 12 years after transplantation (Woodworth et al., 2019). In both these cases, the patients suffered from significant back pain and had to undergo spinal surgery for removal of the mass. Incidences such as these highlight the importance of purification of OECs prior to transplantation. On the other hand, several studies conducted over the years have also suggested that OECs may be more effective if they are mixed with olfactory nerve fibroblasts (Keyvan-Fouladi et al., 2003; Li et al., 2003; Deumens et al., 2006). The importance of purification is conceptualized in the Figure 2. These findings suggest that although purification is essential to avoid any adverse effects following transplantation, certain cell types may provide beneficial effects if co-transplanted with OECs.

An external file that holds a picture, illustration, etc.
Object name is NRR-15-2016-g002.jpg

Consequences of unpurified and purified OEC transplantation.

The OECs have been experimentally transplanted with or without purification. The figure explains this concept with an example of OM-OECs. The unpurified OM-OECs have other cell types present which eventually lead to unfavourable and, in extreme cases, severely debilitating outcomes. A purified cell population, on the other hand, will likely lead to favourable outcomes with tissue repair and functional regain. OEC: Olfactory ensheathing cells; OM: olfactory mucosa.

Out of the 67 included studies, 5 studies obtained OECs from mice and 62 from rats. Out of the 62 studies that used rats as their source of OECs, the OB was the most commonly used source of OECs, with 43 studies using OB-OECs and 22 studies using OM-OECs; one study compared OB-OECs and OM-OECs (Mayeur et al., 2013) and one study did not specify the anatomical source of OECs (Luo et al., 2013). The information regarding sources of cells as used by the reviewed studies is summarized in Additional Table 2.

Additional Table 2

Summary of the numbers of studies using OB and OM from rodents as their OEC sources

AnimalOBOMBothN/M
Rats402011
Mouse3200

N/M: Not mentioned; OB: olfactory bulb; OEC: olfactory ensheathing cell; OM: olfactory mucosa.

The OB was the most frequently used source of OECs for animal experiments. However, from a clinical viewpoint, it would be more desirable to focus on OM-OECs rather than OB-OECs as obtaining OECs from the OB in humans is an invasive procedure that would lead to damage to the olfactory sense. In the one study that specifically compared OM-OECs and OB-OECs, there was no significant difference in functional outcome between the two OEC types. This suggests that, due to the difference in harvesting method, OM-OECs have a better risk to benefit ratio than OB-OECs as harvesting OM-OECs avoids the need for an invasive brain biopsy (Mayeur et al., 2013).

We found that the purification methods used in the reviewed studies differ between OM-OECs and OB-OECs (Additional Table 2). Enrichment and complement lysis were the principal methods used for OM-OECs while differential attachment and immunopurification were more common for purification of OB-OECs (these purification methods are discussed in detail in the next section). Reported purity was highly variable for OM-OECs (5–98%) compared to OB-OECs (60–100%) (Additional Table 3). This also indicates that further optimization of the purification process is warranted for the mucosal OECs, to establish a purification method that consistently improves the purity of OECs.

Additional Table 3

Summary of studies using different purification methods for OB and OM derived OECs

MethodOBOMTotal
Immuno-purification18220
Differential adhesion14014
NT-3 supplement156
Complement lysis033
None used066
N/M11718

N/M: Not mentioned; NT-3: neurotrophin-3; OB: olfactory bulb; OEC: olfactory ensheathing cell; OM: olfactory mucosa.

From the reviewed studies discussed here, it appears that in an experimental setting (animal model), OB-OECs are preferred primarily because of their higher and more consistent purity than OM-OECs. However, due to the harvesting method, OM-OECs are better from a clinical point-of-view.

Purification Methods Differ between Olfactory Mucosa- and Bulb-Derived Olfactory Ensheathing Cell Preparations

Purification of OECs constitutes one of the most significant challenges in establishing OEC transplantation as a treatment for spinal cord injury (Yao et al., 2018). OEC purification can be viewed as a biphasic approach with the first phase being the dissociation of cells from the tissue biopsy, and the second phase being the isolation of pure OEC population from these dissociated cells. Dissociation of cells from the tissue biopsy aims to remove the extracellular substance and adherent structures such as epithelium or meninges, thus releasing cells from their natural scaffolding. For example, separating the epithelium from the lamina propria is involved in the mucosal biopsies, whereas removal of meninges needs to be performed on OB biopsies. Generally, the dissociation also involves enzymatic digestion and/or mechanical dissociation. The strategies used for the next step (establishment of a pure OEC population) include immune-based purification based on cell-specific surface markers, isolation due to differential adhesion properties, chemical enrichment of OECs over other cells in culture, or removal of contaminating cells. In the reviewed papers, the dissociation part of purification process was not mentioned in 14 studies, whereas five further studies reportedly only used mechanical dissociation without the use of any enzymes to dissociate the cells from tissue biopsies (Negredo et al., 2008; Wang et al., 2010; Lang et al., 2013; Tang et al., 2017; Zhang et al., 2017); all five of these studies used OB-OECs. The studies that reported the use of enzymatic dissociation used trypsin, dispase (I and II), collagenase (A, D, I and II), papain or hyaluronidase but with variations in the protocol. For example, trypsin was used for dissociation in 24 of the studies, out of which only two studies harvested cells from mucosal biopsies (Tharion et al., 2011; Muniswami and Tharion, 2018a). In the remaining 22 studies that used trypsin for OB tissue dissociation, 18 studies used trypsin alone, with four studies using trypsin followed by collagenase (Ma et al., 2010; Yazdani et al., 2012; Torres-Espin et al., 2013, 2014).

For the OEC purification protocol, the exact method was not described in 24 of the reviewed studies. Two of these 24 studies reported using pieces of the un-dissociated OM (Iwatsuki et al., 2008; Aoki et al., 2010) which explains the lack of a cell purification step. In contrast, 43 studies reported using several different purification techniques. These techniques can be summarized into the following categories: (1) immunopurification, (2) differential adhesion, (3) OEC enrichment and (4) removal of contaminant cells. The details of different methods of purification are summarized in Additional Table 3.

Immunopurification was the most commonly used purification technique amongst the reviewed papers (20 studies). This method is based on selective expression of key markers by OECs, such as the p75 neurotrophin receptor (p75NTR, also known as the low-affinity nerve growth factor receptor or CD 271), S100β, glial fibrillary acidic protein (GFAP) (Gong et al., 1994; Franceschini and Barnett, 1996; Bianco et al., 2004), SRY-related HMG-box 10 protein (SOX-10) (Barraud et al., 2010; Oprych et al., 2017) and oligodendrocyte marker 4 (O4) (Barnett et al., 1993; Franceschini and Barnett, 1996). One study employed fluorescence-activated cell sorting to sort OECs based on surface expression of O4 (positive selection marker) and galactocerobroside C (as a negative selection marker) (Toft et al., 2013). The remaining 19 studies purified OECs based on expression of p75NTR with five out of these 19 studies using magnetic cell sorting technique (Novikova et al., 2011; Toft et al., 2012; Deumens et al., 2013; Torres-Espin et al., 2013, 2014).

Differential adhesion (also known as differential attachment) was the second most commonly reported purification method. This method relies on the different adhesion time to the cell culture plate for different cell types; removal of media and non-adherent cells at different times leads to partial purification of the target cells. A total of 14 studies used this method, as originally published (Nash et al., 2001), or using a modified version of the same method to purify OECs taken initially from OB. All studies using differential adhesion used OB-OECs.

OEC enrichment of the cultures using neurotrophin-3 (NT-3) was used by six of the studies (Kalincik et al., 2010a, b; Li et al., 2011b; Stamegna et al., 2011; Wu et al., 2011; Cloutier et al., 2016). One of these six studies used this method to purify OB-OECs (Li et al., 2011b), the other five used NT-3 to purify cells from the mucosa. This method originates from an earlier experimental work showing that OECs have receptors for NT-3, BDNF and nerve growth factor, all three of which promote purification and proliferation of OECs in vitro (Bianco et al., 2004). In one study, the authors used transforming growth factor α (TGF-α) followed by five repeated passages to enrich mucosal OECs in the culture (Mayeur et al., 2013); TGF-α has been shown to promote mitosis of olfactory epithelium in vitro (Farbman and Buchholz, 1996).

Removal of contaminant cells was the least common purification method amongst the papers reviewed, being used in only three studies and all for purification of OM-OEC. Complement lysis of fibroblasts by targeting Thy 1.1 surface antigen was reported as a purification method by two studies (Bretzner et al., 2008, 2010), whereas a third study mentioned “removal of fibroblasts” as their purification method (Zhang et al., 2011) which was originally described as a method to purify astrocytes in an older publication (Noble and Murray, 1984).

In summary, out of the 44 studies using OECs from the OB, 11 did not specify the purification method, 18 used immunopurification, 14 used differential adhesion, and one study used NT-3 supplementation. Similarly, out of the 23 studies that reported the use of OM-OECs, seven did not mention any purification methods, six did not purify the OECs, five studies used NT-3 supplement, three used complement lysis method, and only two purified the cells by p75NTR mediated immuno-purification. The summary of the differential adhesion protocols used by all 14 studies is given in Additional Table 4.

Additional Table 4

Summary of the studies using differential adhesion as their purification method, and the details of their protocols

StudyPassage duration (in hours)Supplements

P1P2P3Coating for P3
Tang et al., 2017n/mn/mn/mPLL (ALL 3Ps)AraC
Liu et al., 20171224n/mn/mbFGF
Gu et al., 20171836n/mPLLn/m
Feng et al., 201718–2024–489–12 dPLLAraC (1–2)
Nategh et al., 20161836n/mPLLn/m
Gomes et al., 20162424n/mFibronectinforskolin, BPE
Kang et al., 20152424till day 7PLLAraC (in P2)
Mayeur et al., 2013183610 dPLLn/m
Lang et al., 201312127 dPLL (ALL 3 Ps)n/m
Novikova et al., 20111836–482 dPLLn/m
Wang et al., 201012122 d+1 dPLLAraC (2), forskolin, BPE
Su et al., 20093636n/mPLLforskolin, bFGF
Salehi et al., 200918362 d+1 dPLLn/m

bFGF: Basic fibroblast growth factor; n/m: not mentioned; PLL: poly-L-lysine.

Out of the 20 studies using immunopurification, most studies sorted out OECs from other cells based on p75NTR expression. p75NTR is probably the most well characterized OEC marker, however, it is important to note that OECs of the inner NFL do not express p75NTR (the NFL has an inner and an outer part, both populated by OECs) (Vickland et al., 1991; Franceschini and Barnett, 1996; Au et al., 2002). Furthermore, Schwann cells also express p75NTR, and trigeminal nerve Schwann cells can contaminate OEC preparations as branches of the trigeminal nerve are present in the OM and OB (Ziege et al., 2013). Only one study selected OECs (OB-OECs) based on the expression of O4 and galactocerobroside C (Franceschini and Barnett, 1996). However, more recent work suggests that O4 may not be a suitable marker for OEC purification, since O4 has been suggested to be derived from olfactory axons, and only detected in OECs after phagocytosis of axonal fragments (Wewetzer et al., 2005; Oprych et al., 2017). It could, however, be possible that fluorescence-activated cell sorting sorting for O4 can select OECs if the cells exhibit O4-positive axon-derived debris particles attached to the membrane, in process of being internalized; however, OECs that are not phagocytosing axon debris would not be selected.

Reporting on Purity Is Highly Variable between Studies

Reporting purity of the cells to be transplanted is an important detail in order to link outcomes with the composition of cells in the transplant (Raisman and Li, 2007). However, the biggest challenge in reporting on purity is the lack of clearly established OEC-specific markers (Oprych et al., 2017). This makes it difficult to determine the percentage of OECs within mixed population of cells obtained after any purification process. While OECs have been reported to express certain markers, expression of these markers can differ in vivo and in vitro as well as change significantly over time in culture (Yao et al., 2018). These difficulties have significantly hampered reporting on OEC purity throughout the literature.

Among the 67 studies reviewed here, 23 studies did not report on the purity of their cell populations. Two further studies (Iwatsuki et al., 2008; Aoki et al., 2010) were not able to report the purity since they did not use any purification methods, but rather they transplanted pieces of OM. Two more studies reported the purity of their cell populations in a qualitative manner by stating that all (Liu et al., 2017) or most (Sun et al., 2013) of the cells expressed p75NTR. Only three studies reported a detailed quantification of their cell cultures expressing a number of surface markers useful for identifying OECs such as p75NTR, S100β, GFAP and others (Coutts et al., 2013; Tsai et al., 2017; Muniswami and Tharion, 2018b).

The reported purity of OECs before transplantation ranged from 5% (Yamamoto et al., 2009; Ibrahim et al., 2014) to 99.7% (Roet et al., 2012). Most of the studies (27 studies), however, reported the cell purity to be 90% or more. A study that compared two different purification methods reported that differential adhesion yielded 93–95% pure cells and p75NTR-assisted magnetic bead separation yielded 80% pure cells (Novikova et al., 2011). A separate study that compared OB-OECs with OM-OECs, reported that purity of the OB-OECs increased from 70% to 97% following purification by differential adhesion, and the purity of the OM-OECs increased from 15% to 98% following TGF-α induced purification (Mayeur et al., 2013).

As discussed briefly in the previous section, OB tissue appears to yield OEC cultures with a higher purity than mucosa-derived biopsies. In addition, the purity of bulb-derived preparations also appears more consistent than OM-OEC preparations. Out of the 32 studies that reported on purity in the bulb-derived cell preparations, the average purity was 91.2 ± 3.4%. However, among the 12 studies that reported on purity of OM-OECs, the average purity was 74.2 ± 21.1%.

It is important to note that reported purity may not always be an accurate indicator of the actual purity of the cells present in the culture. For example, four of the studies which used p75NTR-targeted immunopurification method, also used p75NTR immunolabelling to quantify the purified cell population (Negredo et al., 2008; Ma et al., 2010; Roet et al., 2012; Yazdani et al., 2012), and reported 99.7% (Roet et al., 2012) and > 95% (Ma et al., 2010; Yazdani et al., 2012) purity. The problem with this approach is that an independent marker is not used between the purification and identification processes. Using one or more additional markers to quantify the cell purity based on co-localization of the markers can help eliminate bias.

Identification of Olfactory Ensheathing Cells Is Difficult Due to Lack of Specific Markers

Using the optimal method of estimating OEC purity is critical for correlating OEC purity with functional outcomes after transplantation. Since OECs are known to express different markers in vitro and in vivo (Au and Roskams, 2003; Oprych et al., 2017), assessment of OEC purity prior to transplantation should use markers expressed by OECs which have been cultured in vitro. Determination of OEC purity is complicated by the fact that the markers known to be expressed by OECs are not exclusively expressed by OECs and other cell types such as fibroblasts can express the same markers (Yao et al., 2018).

As discussed in the previous section, of the 67 studies reviewed here 19 studies did not describe their method of quantification of OEC purity. The remaining 48 studies used immunolabelling for cell surface markers such as p75NTR, GFAP, S100β and nestin (to label OECs) combined with “negative selection markers” to identify cells that are not OECs, such as fibronectin and Thy-1 (which label fibroblasts). These markers were used alone or in combination. In a few studies, markers other than these were also used, which included, SOX10 (Khankan et al., 2016), TUJ-1 (Toft et al., 2013) and cytokeratin (Toft et al., 2012) to label OECs, and calponin (Coutts et al., 2013) and human natural killer antigen-1 to label cells that are not OECs (HNK-1, also known as CD57 or LEU7, thought to label Schwann cells but not OECs) (Stamegna et al., 2011; Wu et al., 2011).

Nineteen studies used only a single marker for this quantification, with p75NTR used in 18 of these 19 studies. The remaining one study (Su et al., 2009) used S100. The details regarding methods of quantification of purity are summarized in Additional Table 5.

Additional Table 5

Summary of the different markers used by the studies for quantification of purity of the OECs

A Method of quantification
Marker Usedp75NTRGFAPS100NestinFibronectinThy 1OthersN/M
No. of Studies481517263719

B Markers used in the reviewed studies and their indications

Positive selection markersp75NTRGFAPS100NestinSOX10Cytokeratin
Negative selection markersThy 1 (fibroblasts)Fibronectin (fibroblasts)Calponin (fibroblasts)TUJ1 (neurons)HNK-1 (myelinating Schwann cells)

GFAP: Glial fibrillary acidic protein; N/M: not mentioned; OEC: olfactory ensheathing cell.

In the reviewed literature, 29 out of 67 studies reported using a combination of markers, out of which 17 studies used combination of two markers, eight studies used three and four studies used combination of four or more markers. The combination of p75NTR and S100β was used in 16 studies, and in eight out of the 16 studies, those were the only two markers used. Secondly, the combination of p75NTR and GFAP was reported 15 times, out of which seven studies used only these two markers. The remaining two studies used p75NTR with fibronectin to quantify the purity. While some studies used several markers, the study using the most detailed panel to characterize OECs used six markers: p75NTR, S100β, GFAP, fibronectin, Thy-1 and calponin (Coutts et al., 2013). This study reported that most of the OB-OECs (> 90%) were positive for p75NTR, S100β and GFAP; and cells staining positively for fibronectin, Thy 1.1 or calponin (< 1–5%) did not stain for p75NTR.

As there are no specific OEC markers, it is clearly important to use a panel of markers to identify the cells. For example, it is well established that GFAP is a glial cell marker, strongly expressed by astrocytes but weakly expressed by the OECs (Oprych et al., 2017). Using GFAP as a marker for OECs, therefore, can lead to an overestimation of the cell population, especially if the cells originated from the OB, where astrocytes are found in abundance. In five of the reviewed studies, OB-derived cultures contained significant amounts of GFAP-expressing astrocytes (Novikova et al., 2011; Takeoka et al., 2011; Coutts et al., 2013; Tsai et al., 2017; Zheng et al., 2017). It may also be a good idea to use specific markers that are not expressed by OECs but are expressed by the cells that are likely to be present in the tissue biopsy, such as fibronectin, Thy 1, calponin, SMA, HNK-1 and TUJ-1, to identify cells that are not OECs. This option has an added advantage of allowing determination of contaminant cell identity as well. This can be especially relevant when the cells are harvested from the mucosa when purification seems to be more complicated and less consistent. In the future, mass analysis such as RNA sequencing and proteomics, comparing expression patterns between OECs and other cell types, may reveal more cell-specific markers.

Which Cells Accompany Olfactory Ensheathing Cells in Transplants?

If there are cells present in transplants other than the OECs, they can be a significant confounder for the outcome of the experiment, as well as interpretation of the outcome. Especially when the OEC purity is low, knowing the type of contaminating cells becomes more important. Different cells have different proliferation rates and different responses to stressful stimuli, which is why the dynamics of the cell-cell interaction may change significantly upon transplantation into a hostile milieu such as a spinal cord injury site. This affects OECs more since they are known to require intercellular connections to survive in cultures. If the cells such as fibroblasts are present along with OECs, they may have some beneficial effect on the outcome after transplantation, but any immune cells such as microglia or monocytes may lead to an exacerbated immune response following transplant which may even lead to graft rejection. Thus, it is important to identify which cells are present in transplants along with OECs.

A limited number of the reviewed studies discussed contaminating cell types in their purified OECs populations. 50 out of the 67 studies did not mention other cell types. The 17 studies that did discuss the contaminating cell types, usually mentioned fibroblasts or fibroblasts-like cells and Schwann cells (non-myelinating phenotype or negative for HNK-1 expression) as the contaminating cells. Additionally, in some cases, the authors also identified astrocytes (Coutts et al., 2013) and endothelial cells (Novikova et al., 2011) based on their surface marker expression. One particular study (Toft et al., 2012) compared two distinct populations derived from OM and labeled them OM-I and OM-II, which were, in fact, mesenchymal cells of OM, and olfactory epithelial basal cells, respectively. In this study, the authors report that after purification, OM-I cells had a mixture of MSCs and OECs, but do not describe the contaminating cells in OM-II population.

Out of all the studies that used cells from OM, 43.5% (10 out of 23) studies discussed other cell types in the transplantation population. One of these ten studies compared two distinct populations from the OM (Toft et al., 2012). Two studies specified contaminating cells as Schwann cells (Kalincik et al., 2010a; Stamegna et al., 2011), however, only one of those two studies stained for HNK-1, a marker expressed by Schwann cells (Stamegna et al., 2011). The authors in this study also noted that HNK-1 staining does not identify non-myelinating or sensory myelinating Schwann cells. Six more studies discussed fibroblasts as contaminants on the pure OEC population, three of which (Tharion et al., 2011; Ibrahim et al., 2014; Muniswami and Tharion, 2018b), investigated fibronectin expression.

Only seven studies using OB-OECs discussed other cells present with OECs. One study included the possibility of Schwann cell contamination as the authors only described using p75NTR and S100 markers (Zhang et al., 2017). Another study simply mentioned having equal proportions of OECs and olfactory fibroblasts in their cultures, without discussing the markers used for quantification (Collins et al., 2017). Two more studies assumed the presence of fibroblasts (Nategh et al., 2016; Feng et al., 2017), and did not mention the markers used for characterizing OECs after purification. Another study mentioned fibroblasts and endothelial cells as contaminating population (Novikova et al., 2011), although, their marker panel included p75NTR, S100 and GFAP only. One further study confirmed the presence of fibroblasts with fibronectin (Li et al., 2016), and the last study performed a detailed characterization of all cell types present in their cultures by using a six markers panel and defined the contaminant cells as astrocytes and fibroblast-like cells (Coutts et al., 2013).

Most OEC transplantation studies to date (~75%) have not focused on identifying the cells that accompany OECs in transplants, most likely because, as discussed earlier, cell identification is complicated since no specific OEC markers exist. Characterization of the contaminant cells in transplants, however, is important to correlate OEC purity and cell composition with outcomes, and the use of a panel of markers is to date the best strategy to achieve this. Identification of the cells transplanted is also critical to avoid serious side effects (such as accidental transplantation of respiratory epithelium).

Correlation of Olfactory Ensheathing Cell Purity with Transplantation Outcomes

Outcomes after OEC transplantation are typically assessed on a structural (histological) and functional (behavioral) level, taking into account the known behaviors and functions of transplanted OECs. OECs can migrate considerable distances into the injury site where they integrate with the host tissue and interact with damaged axons, as well as with reactive astrocytes and microglia (Barakat et al., 2005; Windus et al., 2007; Chehrehasa et al., 2012). They have been found to repair the damaged axonal tracts, promote axonal sprouting, form a structural “bridge” across injury sites to guide the newly formed axonal branches, limit secondary damage following an injury, preserve spared tissues, and mitigate reactive astroglial scarring (Sasaki et al., 2004; Barakat et al., 2005; Windus et al., 2007, 2011). Hence, studies assessing structural repair in spinal cord injuries following OECs mediated treatments, commonly address (1) cell survival, (2) cell migration, (3) reparative changes in the cord parenchyma, (4) degenerative changes at or near the injury site, and (5) immune or inflammatory reactions associated with the injury as well as OEC transplant.

Similarly, the functional outcomes are generally assessed based on (1) recovery of motor functions, gait (or stepping) pattern, (2) ability to perceive noxious stimuli such as pain or heat, or (3) general sensory perception recovery, and by studying (4) electrophysiological changes of the nerve-muscle tissues.

For the sake of consistency in this review, structural repair is defined as reporting of (1) cell survival, (2) migration (into the cord parenchyma or formation of cell bridges across injury), (3) axonal repair/regeneration, (4) decrease in the defect size, and (5) reduction or regulation of immune and/or inflammatory reaction. Similarly, functional regain is defined as motor recovery, sensory recovery and electrophysiological recordings.

Out of the 56 studies that performed histological analysis, 23 studies addressed (1) cell survival, 15 discussed (2) cell migration, 40 studies commented on (3) axonal regeneration and/or repair, 22 studies investigated effects of OECs in (4) reducing degenerative changes (cell death, cavitation after injury, secondary injury) and 16 studies investigated (5) OEC interactions with immune/inflammatory cells (macrophages, microglia, and/or astrocytes). The majority of the studies analyzed more than one of the structural repair parameters, however, 22 studies only commented on any one of these parameters. Other studies reported bladder and bowel autonomic functions, or other specific functional measures but there were too few to make comparisons.

We here aimed to correlate OEC purity with structural and functional repair after spinal cord injury. Out of all the studies included in this review, 50 (~75%) reported that OEC transplantation resulted in structural and/or functional repair (positive outcomes). The remaining (17) studies reported either no significant improvement or adverse effects such as pain (Additional Table 1).

Poor outcomes – Out of all the reviewed studies, two studies (from the same research group) reported that the structural repair was comparable between acute and delayed transplants (Centenaro et al., 2013), and that the axonal repair could not be linked with the OEC treatments (Centenaro et al., 2011), respectively. Neither of the studies mentioned cell purity. Five more studies reported negative or insignificant outcomes from a structural perspective. One of the five studies (Li et al., 2016) mentioned that the cells failed to survive beyond one week despite the continued evidence of axonal repair and motor function regain; the purity reported here was 60–70%. The remaining majority of studies included here reported positive or desirable histological outcomes following OEC treatments for one or more of the above-mentioned parameters. While fifteen of the 48 studies did not mention the purity of their OEC treatments, the average OEC purity of all the studies that reported a positive outcome was ~91%.

Similarly, from a functional regain viewpoint, 12 studies out of 52, reported non-significant or negative outcomes, however cell purity was not reported for most studies. Of those studies that reported OEC purity, one study sought to use 95% pure OECs (source not specified) to treat neuropathic pain (Luo et al., 2013), but found that OEC treatment resulted in hyperalgesia. A similar study used 95% pure OB-OECs to treat neuropathic pain following a hemi-section injury (Lang et al., 2013) and reported that OECs caused hyperalgesia. Conversely, a study using 90% pure OM-OECs (Wu et al., 2011) found that the treatment alleviated neuropathic pain but did not improve complex goal-oriented skilled locomotion.

Favourable outcomes – Of the 40 studies that reported positive functional outcomes of OEC treatments, 14 studies did not comment on the OEC purity. The lowest reported purity among the remaining 26 studies were 5% (Yamamoto et al., 2009), 50% (Collins et al., 2017) and 60–70% (Li et al., 2016). Two studies reported 75% (Bretzner et al., 2008, 2010) and one study reported > 80% (Amemori et al., 2010) purity of the transplanted OECs, the rest 20 studies had 90–100% pure cultures, with an average purity of ~86.5% including all 26 studies.

Overall, it appears high OEC purity correlates with favourable outcomes, whereas transplanting OECs with a purity of 75% or less are frequently associated with failed recoveries or undesirable outcomes. In addition, using OB-OECs is in some studies correlated with worsened neuropathic pain, whereas OM-OECs may instead alleviate pain. Due to lack of a sufficient number of studies, and the inconsistencies and difficulties in reporting on OEC purity, a concise conclusion regarding OEC purity and structural/functional outcomes of OEC transplantation cannot be made.

Conclusion

We have here reviewed all OEC transplantation studies in rodent models of spinal cord injury over the last decade with a focus on OEC purity. We found that OB-OECs have been more frequently used than the OM-OECs although the use of OB-OECs in humans is problematic due to the invasive and destructive surgery required to obtain them. Immune-based purification methods, often based on expression of p75NTR, were the most common purification techniques for both OB-OECs and OM-OECs. Out of the studies which assessed OEC purity, the majority of studies reported an OEC purity of over 90%, with OB-OEC cultures typically having a higher purity than OM-OECs. However, the lack of cell-specific markers makes both OEC purification and determination of OEC purity challenging tasks, particularly for transplantation of OM-OECs. Robust quantification methods are essential to reliably estimate OEC purity; a panel of several markers is better than the use of a single marker. As per the reviewed literature, the most commonly used markers to identify OECs are p75NTR, S100β and GFAP either by themselves or a combination of any two of the three. Transplantation of OECs that resulted in favourable outcomes had high reported purity whereas studies reporting low purity tended to have poorer outcomes. However, OEC purification is a complex process and thus, reliable purification and quantification methods are essential to improve the therapeutic potential of OEC transplantation for spinal cord injury repair.

Additional files:

Additional file 1: Open peer review report 1.

OPEN PEER REVIEW REPORT 1

Additional Table 1: Summary of source of cells, method of purification, reported purity, method of estimating/ quantification, cells in the mix, key structural and functional outcomes.

Additional Table 1

Summary of source of cells, method of purification, reported purity, method of estimating/ quantification, cells in the mix, key structural and functional outcomes

Additional Table 2: Summary of the numbers of studies using OB and OM from rodents as their OEC sources.

Additional Table 3: Summary of studies using different purification methods for OB and OM derived OECs.

Additional Table 4: Summary of the studies using differential adhesion as their purification method, and the details of their protocols.

Additional Table 5: Summary of the different markers used by the studies for quantification of purity of the OECs.

Footnotes

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open peer reviewer: Ashraf S. Gorgey, Virginia Commonwealth University, USA.

P-Reviewer: Gorgey AS; C-Editors: Zhao M, Li JY; T-Editor: Jia Y

References

1. Amemori T, Jendelova P, Ruzickova K, Arboleda D, Sykova E. Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells does not have synergistic effects after spinal cord injury in the rat. Cytotherapy. 2010;12:212–225. [Abstract] [Google Scholar]
2. Aoki M, Kishima H, Yoshimura K, Ishihara M, Ueno M, Hata K, Yamashita T, Iwatsuki K, Yoshimine T. Limited functional recovery in rats with complete spinal cord injury after transplantation of whole-layer olfactory mucosa: laboratory investigation. J Neurosurg Spine. 2010;12:122–130. [Abstract] [Google Scholar]
3. Au E, Roskams AJ. Olfactory ensheathing cells of the lamina propria in vivo and in vitro. Glia. 2003;41:224–236. [Abstract] [Google Scholar]
4. Au WW, Treloar HB, Greer CA. Sublaminar organization of the mouse olfactory bulb nerve layer. J Comp Neurol. 2002;446:68–80. [Abstract] [Google Scholar]
5. Barakat DJ, Gaglani SM, Neravetla SR, Sanchez AR, Andrade CM, Pressman Y, Puzis R, Garg MS, Bunge MB, Pearse DD. Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord. Cell Transplant. 2005;14:225–240. [Abstract] [Google Scholar]
6. Barbour HR, Plant CD, Harvey AR, Plant GW. Tissue sparing, behavioral recovery, supraspinal axonal sparingregeneration following sub-acute glial transplantation in a model of spinal cord contusion. BMC Neurosci. 2013;14:106. [Europe PMC free article] [Abstract] [Google Scholar]
7. Barnett SC, Hutchins AM, Noble M. Purification of olfactory nerve ensheathing cells from the olfactory bulb. Dev Biol. 1993;155:337–350. [Abstract] [Google Scholar]
8. Barnett SC, Riddell JS. Olfactory ensheathing cells (OECs) and the treatment of CNS injury: advantages and possible caveats. J Anat. 2004;204:57–67. [Abstract] [Google Scholar]
9. Barraud P, Seferiadis AA, Tyson LD, Zwart MF, Szabo-Rogers HL, Ruhrberg C, Liu KJ, Baker CV. Neural crest origin of olfactory ensheathing glia. Proc Natl Acad Sci U S A. 2010;107:21040–21045. [Europe PMC free article] [Abstract] [Google Scholar]
10. Barton MJ, John JS, Clarke M, Wright A, Ekberg J. The glia response after peripheral nerve injury: a comparison between Schwann cells and olfactory ensheathing cells and their uses for neural regenerative therapies. Int J Mol Sci. 2017 103390/ijms18020287. [Europe PMC free article] [Abstract] [Google Scholar]
11. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12:1–21. [Abstract] [Google Scholar]
12. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006;23:635–659. [Abstract] [Google Scholar]
13. Bianco JI, Perry C, Harkin DG, Mackay-Sim A, Féron F. Neurotrophin 3 promotes purification and proliferation of olfactory ensheathing cells from human nose. Glia. 2004;45:111–123. [Abstract] [Google Scholar]
14. Bretzner F, Liu J, Currie E, Roskams AJ, Tetzlaff W. Undesired effects of a combinatorial treatment for spinal cord injury--transplantation of olfactory ensheathing cells and BDNF infusion to the red nucleus. Eur J Neurosci. 2008;28:1795–1807. [Abstract] [Google Scholar]
15. Bretzner F, Plemel JR, Liu J, Richter M, Roskams AJ, Tetzlaff W. Combination of olfactory ensheathing cells with local versus systemic cAMP treatment after a cervical rubrospinal tract injury. J Neurosci Res. 2010;88:2833–2846. [Abstract] [Google Scholar]
16. Canavan HE, Cheng X, Graham DJ, Ratner BD, Castner DG. Cell sheet detachment affects the extracellular matrix: a surface science study comparing thermal liftoff, enzymatic, and mechanical methods. J Biomed Mater Res A. 2005;75:1–13. [Abstract] [Google Scholar]
17. Centenaro LA, da Cunha Jaeger M, Ilha J, de Souza MA, Balbinot LF, do Nascimento PS, Marcuzzo S, Achaval M. Implications of olfactory lamina propria transplantation on hyperreflexia and myelinated fiber regeneration in rats with complete spinal cord transection. Neurochem Res. 2013;38:371–381. [Abstract] [Google Scholar]
18. Centenaro LA, Jaeger Mda C, Ilha J, de Souza MA, Kalil-Gaspar PI, Cunha NB, Marcuzzo S, Achaval M. Olfactory and respiratory lamina propria transplantation after spinal cord transection in rats: effects on functional recovery and axonal regeneration. Brain Res. 2011;1426:54–72. [Abstract] [Google Scholar]
19. Chehrehasa F, Ekberg JA, Lineburg K, Amaya D, Mackay-Sim A, St John JA. Two phases of replacement replenish the olfactory ensheathing cell population after injury in postnatal mice. Glia. 2012;60:322–332. [Abstract] [Google Scholar]
20. Cloutier F, Kalincik T, Lauschke J, Tuxworth G, Cavanagh B, Meedeniya A, Mackay-Sim A, Carrive P, Waite P. Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats. Auton Neurosci. 2016;201:17–23. [Abstract] [Google Scholar]
21. Collins A, Li D, McMahon SB, Raisman G, Li Y. Transplantation of cultured olfactory bulb cells prevents abnormal sensory responses during recovery from dorsal root avulsion in the rat. Cell Transplant. 2017;26:913–924. [Europe PMC free article] [Abstract] [Google Scholar]
22. Coutts DJ, Humphries CE, Zhao C, Plant GW, Franklin RJ. Embryonic-derived olfactory ensheathing cells remyelinate focal areas of spinal cord demyelination more efficiently than neonatal or adult-derived cells. Cell Transplant. 2013;22:1249–1261. [Abstract] [Google Scholar]
23. Danhier P, Copetti T, De Preter G, Leveque P, Feron O, Jordan BF, Sonveaux P, Gallez B. Influence of cell detachment on the respiration rate of tumor and endothelial cells. PLoS One. 2013;8:e53324. [Europe PMC free article] [Abstract] [Google Scholar]
24. Deuis JR, Dvorakova LS, Vetter I. Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci. 2017;10:284. [Europe PMC free article] [Abstract] [Google Scholar]
25. Deumens R, Koopmans GC, Honig WM, Hamers FP, Maquet V, Jerome R, Steinbusch HW, Joosten EA. Olfactory ensheathing cells, olfactory nerve fibroblasts and biomatrices to promote long-distance axon regrowth and functional recovery in the dorsally hemisected adult rat spinal cord. Exp Neurol. 2006;200:89–103. [Abstract] [Google Scholar]
26. Deumens R, Van Gorp SF, Bozkurt A, Beckmann C, Fuhrmann T, Montzka K, Tolba R, Kobayashi E, Heschel I, Weis J, Brook GA. Motor outcome and allodynia are largely unaffected by novel olfactory ensheathing cell grafts to repair low-thoracic lesion gaps in the adult rat spinal cord. Behav Brain Res. 2013;237:185–189. [Abstract] [Google Scholar]
27. Dlouhy BJ, Awe O, Rao RC, Kirby PA, Hitchon PW. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: Case report. J Neurosurg Spine. 2014;21:618–622. [Abstract] [Google Scholar]
28. Doucette JR. The glial cells in the nerve fiber layer of the rat olfactory bulb. Anat Rec. 1984;210:385–391. [Abstract] [Google Scholar]
29. Doucette R. Development of the nerve fiber layer in the olfactory bulb of mouse embryos. J Comp Neurol. 1989;285:514–527. [Abstract] [Google Scholar]
30. Doucette R. Glial influences on axonal growth in the primary olfactory system. Glia. 1990;3:433–449. [Abstract] [Google Scholar]
31. Ekberg JA, St John JA. Crucial roles for olfactory ensheathing cells and olfactory mucosal cells in the repair of damaged neural tracts. Anat Rec (Hoboken) 2014;297:121–128. [Abstract] [Google Scholar]
32. Ekberg JA, St John JA. Olfactory ensheathing cells for spinal cord repair: crucial differences between subpopulations of the glia. Neural Regen Res. 2015;10:1395–1396. [Europe PMC free article] [Abstract] [Google Scholar]
33. Ekberg JA, Amaya D, Chehrehasa F, Lineburg K, Claxton C, Windus LC, Key B, Mackay-Sim A, St John JA. OMP-ZsGreen fluorescent protein transgenic mice for visualisation of olfactory sensory neurons in vivo and in vitro. J Neurosci Methods. 2011;196:88–98. [Abstract] [Google Scholar]
34. Farbman AI, Buchholz JA. Transforming growth factor-alpha and other growth factors stimulate cell division in olfactory epithelium in vitro. J Neurobiol. 1996;30:267–280. [Abstract] [Google Scholar]
35. Feng L, Gan H, Zhao W, Liu Y. Effect of transplantation of olfactory ensheathing cell conditioned medium induced bone marrow stromal cells on rats with spinal cord injury. Mol Med Rep. 2017;16:1661–1668. [Europe PMC free article] [Abstract] [Google Scholar]
36. Fouad K, Pearse DD, Tetzlaff W, Vavrek R. Transplantation and repair: combined cell implantation and chondroitinase delivery prevents deterioration of bladder function in rats with complete spinal cord injury. Spinal Cord. 2009;47:727–732. [Abstract] [Google Scholar]
37. Franceschini IA, Barnett SC. Low-affinity NGF-receptor and E-N-CAM expression define two types of olfactory nerve ensheathing cells that share a common lineage. Dev Biol. 1996;173:327–343. [Abstract] [Google Scholar]
38. Gomes ED, Mendes SS, Leite-Almeida H, Gimble JM, Tam RY, Shoichet MS, Sousa N, Silva NA, Salgado AJ. Combination of a peptide-modified gellan gum hydrogel with cell therapy in a lumbar spinal cord injury animal model. Biomaterials. 2016;105:38–51. [Abstract] [Google Scholar]
39. Gong Q. Culture of mouse olfactory sensory neurons. Curr Protoc Neurosci. 2012 101002/0471142301ns0324s58. [Europe PMC free article] [Abstract] [Google Scholar]
40. Gong Q, Bailey MS, Pixley SK, Ennis M, Liu W, Shipley MT. Localization and regulation of low affinity nerve growth factor receptor expression in the rat olfactory system during development and regeneration. J Comp Neurol. 1994;344:336–348. [Abstract] [Google Scholar]
41. Gorrie CA, Hayward I, Cameron N, Kailainathan G, Nandapalan N, Sutharsan R, Wang J, Mackay-Sim A, Waite PM. Effects of human OEC-derived cell transplants in rodent spinal cord contusion injury. Brain Res. 2010;1337:8–20. [Abstract] [Google Scholar]
42. Granger N, Blamires H, Franklin RJM, Jeffery ND. Autologous olfactory mucosal cell transplants in clinical spinal cord injury: a randomized double-blinded trial in a canine translational model. Brain. 2012;135:3227–3237. [Europe PMC free article] [Abstract] [Google Scholar]
43. Graziadei PP, Graziadei GA. Neurogenesis and neuron regeneration in the olfactory system of mammals. I. Morphological aspects of differentiation and structural organization of the olfactory sensory neurons. J Neurocytol. 1979;8:1–18. [Abstract] [Google Scholar]
44. Graziadei PP, Monti Graziadei GA. Neurogenesis and neuron regeneration in the olfactory system of mammals. III. Deafferentation and reinnervation of the olfactory bulb following section of the fila olfactoria in rat. J Neurocytol. 1980;9:145–162. [Abstract] [Google Scholar]
45. Graziadei PP, Monti Graziadei GA. Neurogenesis and plasticity of the olfactory sensory neurons. Ann N Y Acad Sci. 1985;457:127–142. [Abstract] [Google Scholar]
46. Hamers FPT, Lankhorst AJ, Laar TJv, Veldhuis WB, Gispen WH. Automated quantitative gait analysis during overground locomotion in the rat: its application to spinal cord contusion and transection injuries. J Neurotrauma. 2001;18:187–201. [Abstract] [Google Scholar]
47. Holbrook EH, Rebeiz L, Schwob JE. Office-based olfactory mucosa biopsies. Int Forum Allergy Rhinol. 2016;6:646–653. [Europe PMC free article] [Abstract] [Google Scholar]
48. Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, Lyu PC, Wu CL, Lu YC, Lin ST, Lin CW, Lai CH, Chang HT, Chou HC, Chan HL. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci. 2010;17:36. [Europe PMC free article] [Abstract] [Google Scholar]
49. Ibrahim A, Li D, Collins A, Tabakow P, Raisman G, Li Y. Comparison of olfactory bulbar and mucosal cultures in a rat rhizotomy model. Cell Transplant. 2014;23:1465–1470. [Abstract] [Google Scholar]
50. Iwatsuki K, Yoshimine T, Kishima H, Aoki M, Yoshimura K, Ishihara M, Ohnishi Y, Lima C. Transplantation of olfactory mucosa following spinal cord injury promotes recovery in rats. Neuroreport. 2008;19:1249–1252. [Abstract] [Google Scholar]
51. Kalincik T, Choi EA, Feron F, Bianco J, Sutharsan R, Hayward I, Mackay-Sim A, Carrive P, Waite PM. Olfactory ensheathing cells reduce duration of autonomic dysreflexia in rats with high spinal cord injury. Auton Neurosci. 2010a;154:20–29. [Abstract] [Google Scholar]
52. Kalincik T, Jozefcikova K, Sutharsan R, Mackay-Sim A, Carrive P, Waite PM. Selected changes in spinal cord morphology after T4 transection and olfactory ensheathing cell transplantation. Auton Neurosci. 2010b;158:31–38. [Abstract] [Google Scholar]
53. Keyvan-Fouladi N, Raisman G, Li Y. Functional repair of the corticospinal tract by delayed transplantation of olfactory ensheathing cells in adult rats. J Neurosci. 2003;23:9428–9434. [Europe PMC free article] [Abstract] [Google Scholar]
54. Khankan RR, Griffis KG, Haggerty-Skeans JR, Zhong H, Roy RR, Edgerton VR, Phelps PE. Olfactory ensheathing cell transplantation after a complete spinal cord transection mediates neuroprotective and immunomodulatory mechanisms to facilitate regeneration. J Neurosci. 2016;36:6269–6286. [Europe PMC free article] [Abstract] [Google Scholar]
55. Kwon B, Oxland T, Tetzlaff W. Animal models used in spinal cord regeneration research. Spine. 2002;27:1504–1510. [Abstract] [Google Scholar]
56. Lakatos A, Franklin RJ, Barnett SC. Olfactory ensheathing cells and Schwann cells differ in their in vitro interactions with astrocytes. Glia. 2000;32:214–225. [Abstract] [Google Scholar]
57. Lakatos A, Barnett SC, Franklin RJM. Olfactory ensheathing cells induce less host astrocyte response and chondroitin sulphate proteoglycan expression than Schwann cells following transplantation into adult CNS white matter. Exp Neurol. 2003;184:237–246. [Abstract] [Google Scholar]
58. Lang BC, Zhang Z, Lv LY, Liu J, Wang TY, Yang LH, Liao DQ, Zhang WS, Wang TH. OECs transplantation results in neuropathic pain associated with BDNF regulating ERK activity in rats following cord hemisection. BMC Neurosci. 2013;14:80. [Europe PMC free article] [Abstract] [Google Scholar]
59. Lankford KL, Sasaki M, Radtke C, Kocsis JD. Olfactory ensheathing cells exhibit unique migratory, phagocytic, and myelinating properties in the X-irradiated spinal cord not shared by Schwann cells. Glia. 2008;56:1664–1678. [Abstract] [Google Scholar]
60. Leung JY, Chapman JA, Harris JA, Hale D, Chung RS, West AK, Chuah MI. Olfactory ensheathing cells are attracted to, and can endocytose, bacteria. Cell Mol Life Sci. 2008;65:2732–2739. [Abstract] [Google Scholar]
61. Li BC, Li Y, Chen LF, Chang JY, Duan ZX. Olfactory ensheathing cells can reduce the tissue loss but not the cavity formation in contused spinal cord of rats. J Neurol Sci. 2011a;303:67–74. [Abstract] [Google Scholar]
62. Li BC, Xu C, Zhang JY, Li Y, Duan ZX. Differing Schwann cells and olfactory ensheathing cells behaviors, from interacting with astrocyte, produce similar improvements in contused rat spinal cord’s motor function. J Mol Neurosci. 2012;48:35–44. [Abstract] [Google Scholar]
63. Li Y, Bao J, Khatibi NH, Chen L, Wang H, Duan Y, Huang H, Zhou C. Olfactory ensheathing cell transplantation into spinal cord prolongs the survival of mutant SOD1(G93A) ALS rats through neuroprotection and remyelination. Anat Rec (Hoboken) 2011b;294:847–857. [Abstract] [Google Scholar]
64. Li Y, Decherchi P, Raisman G. Transplantation of olfactory ensheathing cells into spinal cord lesions restores breathing and climbing. J Neurosci. 2003;23:727–731. [Europe PMC free article] [Abstract] [Google Scholar]
65. Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science. 1997;277:2000–2002. [Abstract] [Google Scholar]
66. Li Y, Field PM, Raisman G. Olfactory ensheathing cells and olfactory nerve fibroblasts maintain continuous open channels for regrowth of olfactory nerve fibres. Glia. 2005;52:245–251. [Abstract] [Google Scholar]
67. Li Y, Li D, Raisman G. Functional repair of rat corticospinal tract lesions does not require permanent survival of an immunoincompatible transplant. Cell Transplant. 2016;25:293–299. [Abstract] [Google Scholar]
68. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med. 2006;29:191–203. [Europe PMC free article] [Abstract] [Google Scholar]
69. Liu T, Ji ZQ, Ahsan SM, Zhang Y, Zhang P, Fan ZH, Shen YX. Intrathecal transplantation of olfactory ensheathing cells by lumbar puncture for thoracic spinal cord injury in mice. J Neurorest. 2017;5:103–109. [Google Scholar]
70. Luo Y, Zou Y, Yang L, Liu J, Liu S, Liu J, Zhou X, Zhang W, Wang T. Transplantation of NSCs with OECs alleviates neuropathic pain associated with NGF downregulation in rats following spinal cord injury. Neurosci Lett. 2013;549:103–108. [Abstract] [Google Scholar]
71. Ma YH, Zhang Y, Cao L, Su JC, Wang ZW, Xu AB, Zhang SC. Effect of neurotrophin-3 genetically modified olfactory ensheathing cells transplantation on spinal cord injury. Cell Transplant. 2010;19:167–177. [Abstract] [Google Scholar]
72. Mayeur A, Duclos C, Honore A, Gauberti M, Drouot L, do Rego JC, Bon-Mardion N, Jean L, Verin E, Emery E, Lemarchant S, Vivien D, Boyer O, Marie JP, Guerout N. Potential of olfactory ensheathing cells from different sources for spinal cord repair. PLoS One. 2013;8:e62860. [Europe PMC free article] [Abstract] [Google Scholar]
73. Metz GA, Whishaw IQ. The ladder rung walking task: a scoring system and its practical application. J Vis Exp. 2009 103791/1204. [Europe PMC free article] [Abstract] [Google Scholar]
74. Motyan JA, Toth F, Tozser J. Research applications of proteolytic enzymes in molecular biology. Biomolecules. 2013;3:923–942. [Europe PMC free article] [Abstract] [Google Scholar]
75. Muniswami DM, Tharion G. Therapeutic effect of cell transplantation and chondroitinase in rat spinal cord injury. Int J Appl Basic Med Res. 2018a;8:220–226. [Europe PMC free article] [Abstract] [Google Scholar]
76. Muniswami DM, Tharion G. Functional recovery following the transplantation of olfactory ensheathing cells in rat spinal cord injury model. Asian Spine J. 2018b;12:998–1009. [Europe PMC free article] [Abstract] [Google Scholar]
77. Munoz-Quiles C, Santos-Benito FF, Liamusi MB, Ramon-Cueto A. Chronic spinal injury repair by olfactory bulb ensheathing glia and feasibility for autologous therapy. J Neuropathol Exp Neurol. 2009;68:1294–1308. [Europe PMC free article] [Abstract] [Google Scholar]
78. Nash HH, Borke RC, Anders JJ. New method of purification for establishing primary cultures of ensheathing cells from the adult olfactory bulb. Glia. 2001;34:81–87. [Abstract] [Google Scholar]
79. Nategh M, Firouzi M, Naji-Tehrani M, Zanjan LO, Hassannejad Z, Nabian MH, Zadega SA, Karimi M, Rahimi-Movaghar V. Subarachnoid space transplantation of Schwann andor olfactory ensheathing cells following severe spinal cord injury fails to improve locomotor recovery in rats. Acta Med Iran. 2016;54:562–569. [Abstract] [Google Scholar]
80. Negredo P, Rivero JL, Gonzalez B, Ramon-Cueto A, Manso R. Slow- and fast-twitch rat hind limb skeletal muscle phenotypes 8 months after spinal cord transection and olfactory ensheathing glia transplantation. J Physiol. 2008;586:2593–2610. [Abstract] [Google Scholar]
81. Noble M, Murray K. Purified astrocytes promote the in vitro division of a bipotential glial progenitor cell. EMBO J. 1984;3:2243–2247. [Europe PMC free article] [Abstract] [Google Scholar]
82. Novikova LN, Lobov S, Wiberg M, Novikov LN. Efficacy of olfactory ensheathing cells to support regeneration after spinal cord injury is influenced by method of culture preparation. Exp Neurol. 2011;229:132–142. [Abstract] [Google Scholar]
83. Oprych K, Cotfas D, Choi D. Common olfactory ensheathing glial markers in the developing human olfactory system. Brain Struct Funct. 2017;222:1877–1895. [Europe PMC free article] [Abstract] [Google Scholar]
84. Panni P, Ferguson IA, Beacham I, Mackay-Sim A, Ekberg JA, St John JA. Phagocytosis of bacteria by olfactory ensheathing cells and Schwann cells. Neurosci Lett. 2013;539:65–70. [Abstract] [Google Scholar]
85. Raisman G, Li Y. Repair of neural pathways by olfactory ensheathing cells. Nat Rev Neurosci. 2007;8:312–319. [Abstract] [Google Scholar]
86. Roet KC, Eggers R, Verhaagen J. Noninvasive bioluminescence imaging of olfactory ensheathing glia and schwann cells following transplantation into the lesioned rat spinal cord. Cell Transplant. 2012;21:1853–1865. [Abstract] [Google Scholar]
87. Sasaki M, Lankford KL, Zemedkun M, Kocsis JD. Identified olfactory ensheathing cells transplanted into the transected dorsal funiculus bridge the lesion and form myelin. J Neurosci. 2004;24:8485–8493. [Europe PMC free article] [Abstract] [Google Scholar]
88. Stamegna JC, Felix MS, Roux-Peyronnet J, Rossi V, Feron F, Gauthier P, Matarazzo V. Nasal OEC transplantation promotes respiratory recovery in a subchronic rat model of cervical spinal cord contusion. Exp Neurol. 2011;229:120–131. [Abstract] [Google Scholar]
89. Stepanova OV, Voronova АD, Chadin AV, Valikhov MP, Abakumov MA, Reshetov IV, Chekhonin VP. Isolation of rat olfactory ensheathing cells and their use in the therapy of posttraumatic cysts of the spinal cord. Bull Exp Biol Med. 2018;165:132–135. [Abstract] [Google Scholar]
90. Su Z, Yuan Y, Chen J, Cao L, Zhu Y, Gao L, Qiu Y, He C. Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat. PLoS One. 2009;4:e8141. [Europe PMC free article] [Abstract] [Google Scholar]
91. Sun T, Ye C, Zhang Z, Wu J, Huang H. Cotransplantation of olfactory ensheathing cells and Schwann cells combined with treadmill training promotes functional recovery in rats with contused spinal cords. Cell Transplant. 2013;22:S27-S38. [Abstract] [Google Scholar]
92. Tabakow P, Jarmundowicz W, Czapiga B, Fortuna W, Miedzybrodzki R, Czyz M, Huber J, Szarek D, Okurowski S, Szewczyk P, Gorski A, Raisman G. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplant. 2013;22:1591–1612. [Abstract] [Google Scholar]
93. Tabakow P, Raisman G, Fortuna W, Czyz M, Huber J, Li D, Szewczyk P, Okurowski S, Miedzybrodzki R, Czapiga B, Salomon B, Halon A, Li Y, Lipiec J, Kulczyk A, Jarmundowicz W. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. Cell Transplant. 2014;23:1631–1655. [Abstract] [Google Scholar]
94. Takeoka A, Jindrich DL, Munoz-Quiles C, Zhong H, van den Brand R, Pham DL, Ziegler MD, Ramon-Cueto A, Roy RR, Edgerton VR, Phelps PE. Axon regeneration can facilitate or suppress hindlimb function after olfactory ensheathing glia transplantation. J Neurosci. 2011;31:4298–4310. [Europe PMC free article] [Abstract] [Google Scholar]
95. Takeoka A, Kubasak MD, Zhong H, Kaplan J, Roy RR, Phelps PE. Noradrenergic innervation of the rat spinal cord caudal to a complete spinal cord transection: effects of olfactory ensheathing glia. Exp Neurol. 2010;222:59–69. [Europe PMC free article] [Abstract] [Google Scholar]
96. Takeoka A, Kubasak MD, Zhong H, Roy RR, Phelps PE. Serotonergic innervation of the caudal spinal stump in rats after complete spinal transection: effect of olfactory ensheathing glia. J Comp Neurol. 2009;515:664–676. [Europe PMC free article] [Abstract] [Google Scholar]
97. Tang YY, Guo WX, Lu ZF, Cheng MH, Shen YX, Zhang YZ. Ginsenoside Rg1 promotes the migration of olfactory ensheathing cells via the PI3K/Akt pathway to repair rat spinal cord injury. Biol Pharm Bull. 2017;40:1630–1637. [Abstract] [Google Scholar]
98. Tharion G, Indirani K, Durai M, Meenakshi M, Devasahayam S, Prabhav N, Solomons C, Bhattacharji S. Motor recovery following olfactory ensheathing cell transplantation in rats with spinal cord injury. Neurol India. 2011;59:566–572. [Abstract] [Google Scholar]
99. Thornton MA, Mehta MD, Morad TT, Ingraham KL, Khankan RR, Griffis KG, Yeung AK, Zhong H, Roy RR, Edgerton VR, Phelps PE. Evidence of axon connectivity across a spinal cord transection in rats treated with epidural stimulation and motor training combined with olfactory ensheathing cell transplantation. Exp Neurol. 2018;309:119–133. [Europe PMC free article] [Abstract] [Google Scholar]
100. Toft A, Scott DT, Barnett SC, Riddell JS. Electrophysiological evidence that olfactory cell transplants improve function after spinal cord injury. Brain. 2007;130:970–984. [Abstract] [Google Scholar]
101. Toft A, Tome M, Barnett SC, Riddell JS. A comparative study of glial and non-neural cell properties for transplant-mediated repair of the injured spinal cord. Glia. 2013;61:513–528. [Abstract] [Google Scholar]
102. Toft A, Tome M, Lindsay SL, Barnett SC, Riddell JS. Transplant-mediated repair properties of rat olfactory mucosal OM-I and OM-II sphere-forming cells. J Neurosci Res. 2012;90:619–631. [Abstract] [Google Scholar]
103. Torres-Espin A, Hernandez J, Navarro X. Gene expression changes in the injured spinal cord following transplantation of mesenchymal stem cells or olfactory ensheathing cells. PLoS One. 2013;8:e76141. [Europe PMC free article] [Abstract] [Google Scholar]
104. Torres-Espin A, Redondo-Castro E, Hernandez J, Navarro X. Bone marrow mesenchymal stromal cells and olfactory ensheathing cells transplantation after spinal cord injury--a morphological and functional comparison in rats. Eur J Neurosci. 2014;39:1704–1717. [Abstract] [Google Scholar]
105. Tsai MJ, Huang CT, Huang YS, Weng CF, Shyue SK, Huang MC, Liou DY, Lin YR, Cheng CH, Kuo HS, Lin YL, Lee MJ, Huang WH, Huang WC, Cheng H. Improving the regenerative potential of olfactory ensheathing cells by overexpressing prostacyclin synthetase and its application in spinal cord repair. J Biomed Sci. 2017;24:34. [Europe PMC free article] [Abstract] [Google Scholar]
106. Vickland H, Westrum LE, Kott JN, Patterson SL, Bothwell MA. Nerve growth factor receptor expression in the young and adult rat olfactory system. Brain Res. 1991;565:269–279. [Abstract] [Google Scholar]
107. Vincent AJ, Choi-Lundberg DL, Harris JA, West AK, Chuah MI. Bacteria and PAMPs activate nuclear factor kappaB and Gro production in a subset of olfactory ensheathing cells and astrocytes but not in Schwann cells. Glia. 2007;55:905–916. [Abstract] [Google Scholar]
108. Voronova AD, Valikhov MP, Stepanova OV, Mel’nikov PA, Chadin AV, Sidoruk KN, Semkina AS, Abakumov MA, Reshetov IV, Chekhonin VP. Survival and migration of rat olfactory ensheathing cells after transplantation into posttraumatic cysts in the spinal cord. Bull Exp Biol Med. 2018;166:118–123. [Abstract] [Google Scholar]
109. Wang G, Ao Q, Gong K, Zuo H, Gong Y, Zhang X. Synergistic effect of neural stem cells and olfactory ensheathing cells on repair of adult rat spinal cord injury. Cell Transplant. 2010;19:1325–1337. [Abstract] [Google Scholar]
110. Wewetzer K, Kern N, Ebel C, Radtke C, Brandes G. Phagocytosis of O4+ axonal fragments in vitro by p75- neonatal rat olfactory ensheathing cells. Glia. 2005;49:577–587. [Abstract] [Google Scholar]
111. Windus LC, Chehrehasa F, Lineburg KE, Claxton C, Mackay-Sim A, Key B, St John JA. Stimulation of olfactory ensheathing cell motility enhances olfactory axon growth. Cell Mol Life Sci. 2011;68:3233–3247. [Abstract] [Google Scholar]
112. Windus LC, Lineburg KE, Scott SE, Claxton C, Mackay-Sim A, Key B, St John JA. Lamellipodia mediate the heterogeneity of central olfactory ensheathing cell interactions. Cell Mol Life Sci. 2010;67:1735–1750. [Abstract] [Google Scholar]
113. Windus LC, Claxton C, Allen CL, Key B, St John JA. Motile membrane protrusions regulate cell-cell adhesion and migration of olfactory ensheathing glia. Glia. 2007;55:1708–1719. [Abstract] [Google Scholar]
114. Winstead W, Marshall CT, Lu CL, Klueber KM, Roisen FJ. Endoscopic biopsy of human olfactory epithelium as a source of progenitor cells. Am J Rhinol. 2005;19:83–90. [Abstract] [Google Scholar]
115. Woodworth CF, Jenkins G, Barron J, Hache N. Intramedullary cervical spinal mass after stem cell transplantation using an olfactory mucosal cell autograft. CMAJ. 2019;191:E761-764. [Europe PMC free article] [Abstract] [Google Scholar]
116. Wu A, Lauschke JL, Gorrie CA, Cameron N, Hayward I, Mackay-Sim A, Waite PME. Delayed olfactory ensheathing cell transplants reduce nociception after dorsal root injury. Exp Neurol. 2011;229:143–157. [Abstract] [Google Scholar]
117. Yamamoto M, Raisman G, Li D, Li Y. Transplanted olfactory mucosal cells restore paw reaching function without regeneration of severed corticospinal tract fibres across the lesion. Brain Res. 2009;1303:26–31. [Abstract] [Google Scholar]
118. Yao R, Murtaza M, Velasquez JT, Todorovic M, Rayfield A, Ekberg J, Barton M, St John J. Olfactory ensheathing cells for spinal cord injury: sniffing out the issues. Cell Transplant. 2018;27:879–889. [Europe PMC free article] [Abstract] [Google Scholar]
119. Yazdani SO, Pedram M, Hafizi M, Kabiri M, Soleimani M, Dehghan MM, Jahanzad I, Gheisari Y, Hashemi SM. A comparison between neurally induced bone marrow derived mesenchymal stem cells and olfactory ensheathing glial cells to repair spinal cord injuries in rat. Tissue Cell. 2012;44:205–213. [Abstract] [Google Scholar]
120. Zhang J, Chen H, Duan Z, Chen K, Liu Z, Zhang L, Yao D, Li B. The effects of co-transplantation of olfactory ensheathing cells and Schwann cells on local inflammation environment in the contused spinal cord of rats. Mol Neurobiol. 2017;54:943–953. [Abstract] [Google Scholar]
121. Zhang SX, Huang F, Gates M, Holmberg EG. Scar ablation combined with LP/OEC transplantation promotes anatomical recovery and P0-positive myelination in chronically contused spinal cord of rats. Brain Res. 2011;1399:1–14. [Abstract] [Google Scholar]
122. Zheng Z, Du X, Zhang K, Wang X, Chen Y, Kuang N, Fan T, Sun B. Olfactory ensheathing cell transplantation inhibits P2X4 receptor overexpression in spinal cord injury rats with neuropathic pain. Neurosci Lett. 2017;651:171–176. [Abstract] [Google Scholar]
123. Ziege S, Baumgartner W, Wewetzer K. Toward defining the regenerative potential of olfactory mucosa: establishment of Schwann cell-free adult canine olfactory ensheathing cell preparations suitable for transplantation. Cell Transplant. 2013;22:355–367. [Abstract] [Google Scholar]
124. Ziegler MD, Hsu D, Takeoka A, Zhong H, Ramón-Cueto A, Phelps PE, Roy RR, Edgerton VR. Further evidence of olfactory ensheathing glia facilitating axonal regeneration after a complete spinal cord transection. Exp Neurol. 2011;229:109–119. [Europe PMC free article] [Abstract] [Google Scholar]

Articles from Neural Regeneration Research are provided here courtesy of Wolters Kluwer -- Medknow Publications

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/82902008
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/82902008

Article citations


Go to all (11) article citations

Data 


Data behind the article

This data has been text mined from the article, or deposited into data resources.

Similar Articles 


To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.